India Oncology Market 2026-2034: Expected to Reach USD 30.01 Billion, Driven at 10.45% CAGR

According to the latest research report titled "India Oncology Market Size, Share, Trends and Forecast by Cancer Diagnostics and Treatment, Cancer Type, End Use, and Region, 2026-2034," the report provides a comprehensive analysis of the market's growth potential, emerging trends, and competitive landscape shaping the industry.

How Big is the India Oncology Market?

The India oncology market size was valued at USD 11.73 Billion in 2025 and is projected to reach USD 30.01 Billion by 2034, growing at a compound annual growth rate (CAGR) of 10.45% during the forecast period 2026-2034.

The market growth is driven by the increasing incidence of cancer, improving healthcare infrastructure, adoption of innovative technologies, government initiatives in the healthcare sector, expanding insurance coverage, and investments in personalized medicine improving the accessibility and affordability of treatments.

Evaluate Market Opportunity with the Business Sample Report: https://www.imarcgroup.com/india-oncology-market/requestsample

What are the Latest Emerging Trends in India Oncology Market?

• Rising Adoption of Precision Medicine and Targeted Therapies

India's oncology landscape is witnessing a significant shift toward precision medicine, with growing utilization of genomic profiling and biomarker-driven treatment approaches. In February 2026, Metropolis Healthcare Limited unveiled its new Centre of Genomics and hosted a multi-specialty genomics symposium aimed at accelerating the adoption of advanced genomic diagnostics to inform personalized cancer care pathways across India.

• Expansion of Digital Health and AI-Driven Cancer Diagnostics

Artificial intelligence and digital health technologies are increasingly being integrated into cancer diagnostics and treatment planning across India. In August 2025, diagnostics leader Dr. Lal PathLabs introduced a deep learning-based AI module to detect lymph node metastasis across multiple cancer types, helping identify spread earlier and with higher accuracy in clinical workflows.

• Growth of Biosimilars and Affordable Oncology Drug Development

The expanding availability of biosimilar oncology drugs is transforming treatment accessibility in India by offering cost-effective alternatives to expensive biologic therapies. In September 2025, Alkem Laboratories launched Pertuza, a pertuzumab biosimilar for HER2-positive breast cancer in India, developed indigenously to expand access to a critical targeted therapy at lower cost.

What Growth Factors are Driving India Oncology Market?

• Rising Cancer Incidence and Growing Disease Burden

India is witnessing an increasing trend in cancer incidence due to demographic changes including aging and urbanization. According to recent findings from the Indian Council of Medical Research (ICMR), India recorded around 14.6 lakh new cancer cases in 2022, with one in nine people now estimated to be at lifetime risk of developing cancer, underscoring the growing burden driven by lifestyle and environmental factors.

• Expanding Government Health Programs and Policy Support

The Indian government is playing a crucial role in improving cancer care infrastructure through specific health programs, financial support, and policy changes. In February 2026, the Haryana government inaugurated 22 day-care cancer centres across 17 districts to provide free chemotherapy, follow-up treatment, and supportive care locally, reducing travel burdens and out-of-pocket expenses for patients.

• Advancements in Treatment Technologies and Drug Innovation

The emergence of innovative technologies in cancer treatment is rapidly transforming India's oncology landscape, with the launch of new immunotherapies, targeted therapies, antibody-drug conjugates, and cell therapies offering more treatment options to physicians.

How Will the India Oncology Market Evolve in the Coming Years?

The India oncology market is set for sustained growth, driven by continuous advancements in healthcare infrastructure, rising government investments in cancer care, and increasing adoption of innovative treatment modalities. Expanding insurance coverage, growing emphasis on early diagnosis, and the establishment of specialized oncology centres are expected to further accelerate market expansion. The integration of precision medicine, development of affordable biosimilar therapies, and strengthening of public health programs focused on cancer prevention and screening are creating a more supportive environment for long-term market development.

With the market projected to grow from USD 11.73 Billion in 2025 to USD 30.01 Billion by 2034, the industry will benefit from the increasing development of domestic gene therapies and biosimilar portfolios, expansion of AI-driven diagnostics and digital health platforms, growing public-private partnerships improving cancer care infrastructure, and India's strengthening position as an emerging destination for cancer research, clinical trials, and oncology innovation.

India Oncology Market Segmentation

Cancer Type

• Lung Cancer
• Prostate Cancer
• Colon and Rectal Cancer
• Gastric Cancer
• Esophageal Cancer
• Liver Cancer
• Breast Cancer
• Others

End Use

• Hospitals
• Diagnostic Laboratories
• Diagnostic Imaging Centers
• Academia
• Specialty Clinics
• Others

Regional Insights

• North India
• South India
• East India
• West India

Recent Developments & News

• January 2026: Zydus Lifesciences launched Tishtha, the world's first biosimilar of the immuno-oncology drug nivolumab in India to treat multiple cancers, at about one-fourth the cost of the original, aiming to expand access and significantly reduce the treatment burden for patients requiring immunotherapy across diverse cancer indications.

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Key Highlights of the Report

• Comprehensive quantitative analysis of historical and current market trends
• Detailed segment-wise market assessment by cancer diagnostics and treatment, cancer type, end use, and region
• Market growth drivers, challenges, and opportunities analyzed thoroughly
• Porter's Five Forces analysis to assess competitive rivalry and market attractiveness
• Competitive landscape overview with positioning and strategies of key market players

Get Custom Report Based on Your Interest: https://www.imarcgroup.com/request?type=report&id=45268&flag=E

Customization Note

If you require any specific information not covered within the report's scope, it will be provided as part of the customization.

Frequently Asked Questions (FAQs)

Q1. What is the size of the India oncology market?
A. The India oncology market size was valued at USD 11.73 Billion in 2025.

Q2. What is the expected growth rate of the market?
A. The market is projected to grow at a CAGR of 10.45% from 2026-2034, reaching USD 30.01 Billion by 2034.

Q3. What factors are driving the growth of the market?
A. Key factors include rising cancer incidence driven by tobacco use, lifestyle changes, aging demographics, and environmental carcinogens creating sustained demand for oncology solutions, expanding government health programs and insurance coverage improving treatment accessibility.

Q4. Which segment dominates the India oncology market?
A. Cancer treatment dominates the cancer diagnostics and treatment segment with a 64.9% share in 2025. Lung cancer leads by cancer type at 18.7%, hospitals dominate the end-use segment at 53.6%, and West India leads regionally with a 32.4% share driven by premier cancer care institutions and advanced healthcare infrastructure.

Q5. What are the major challenges facing the India oncology market?
A. Major challenges include high costs of advanced cancer treatments including immunotherapies and cell-based therapies creating financial hardship for a large proportion of patients, significant disparities in healthcare infrastructure between urban and rural areas compelling patients to travel long distances for care.

Get Samples of Our Latest In-Depth Reports On Related Topics:

✤ India Teleradiology Market: https://www.imarcgroup.com/india-teleradiology-market/requestsample

✤ India Cell Therapy Market: https://www.imarcgroup.com/india-cell-therapy-market/requestsample

✤ India Microbiology Testing Market: https://www.imarcgroup.com/india-microbiology-testing-market/requestsample

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel: (D) +91 120 433 0800
United States: +1-201-971-6302

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

This release was published on openPR.